Biostax (BTAX) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 14, 2020
Cover [Abstract]
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	0001559356
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		457,578
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 45,267	$ 4,925
Total current assets	45,267	4,925
Fixed Assets:
Computer equipment, net of accumulated depreciation of $12,840 and 12,522 respectively	373	691
Deposits	200	200
Total assets	45,840	5,816
Current Liabilities:
Accounts payable	2,776,837	2,655,949
Accrued liabilities	4,994,349	4,646,771
Net payables due to related parties	76,171	48,217
Notes payable, net of debt discount	5,580,439	5,545,371
Derivative liability	1,903,085	798,126
Total current liabilities	15,330,881	13,694,437
Total liabilities	15,330,881	13,694,437
Commitments and Contingencies (Note 12)
Stockholders' Deficit:
Common stock - par value $0.0001; 750,000,000 shares authorized; 457,578 and 457,578 shares issued and outstanding respectively	46	46
Additional paid in capital	370,908,099	370,908,099
Stock issuances due	10,303	10,303
Accumulated deficit	(386,203,489)	(384,607,069)
Total stockholders' deficit	(15,285,041)	(13,688,621)
Total liabilities and stockholders' deficit	$ 45,840	$ 5,816

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 12,840	$ 12,522
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	457,578	457,578
Common stock, shares outstanding	457,578	457,578

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating expenses
Selling, general and administrative	$ 21,790	$ 496,996	$ 385,427	$ 983,581
Research and development expense	(3,944)		27,566
Stock issued for services G&A				120,000
Depreciation and amortization expense	160	304	319	691
Total operating expense	18,006	497,300	413,312	1,104,272
Loss from operations	(18,006)	(497,300)	(413,312)	(1,104,272)
Other income (expense):
Interest expense	(126,964)	(157,145)	(213,149)	(272,354)
Finance charges	(137,397)		(137,397)
Gain/(Loss) on valuation derivative	(521,179)	(170,264)	(832,562)	(157,492)
Total other expense	(785,540)	(327,409)	(1,183,108)	(429,846)
Net loss	(803,546)	(824,709)	(1,596,420)	(1,534,118)
Net loss attributable to common stockholders	$ (803,546)	$ (824,709)	$ (1,596,420)	$ (1,534,118)
Basic and diluted loss per share attributable to common stockholders	$ (1.76)	$ (1.81)	$ (3.49)	$ (3.40)
Weighted average number of shares outstanding	457,578	455,578	457,578	451,624

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock To Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 44	$ 369,924,426	$ 35,303		$ (381,210,411)		$ (11,250,638)
Balance, shares at Dec. 31, 2018	434,323
Issuance of common stock for prepaid services		120,000					120,000
Issuance of common stock for prepaid services, shares	3,000
Issuance of warrants in connection with debt agreement		73,000					73,000
Issuance of common stock in exchange for debt	$ 2	62,432					62,434
Issuance of common stock in exchange for debt, shares	18,225
Net loss					(1,534,118)		(1,534,118)
Balance at Jun. 30, 2019	$ 46	370,179,858	35,303		(382,744,529)		(12,529,322)
Balance, shares at Jun. 30, 2019	455,578
Balance at Dec. 31, 2019	$ 46	370,908,099	10,303		(384,607,069)		(13,688,621)
Balance, shares at Dec. 31, 2019	457,578
Net loss					(1,596,420)		(1,596,420)
Balance at Jun. 30, 2020	$ 46	$ 370,908,099	$ 10,303		$ (386,203,489)		$ (15,285,041)
Balance, shares at Jun. 30, 2020	457,578

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (803,546)	$ (824,709)	$ (1,596,420)	$ (1,534,118)
Adjustments to reconcile net loss to net cash flows from/ (used in) operating activities:
Depreciation	319	691	319	691
Amortization of debt discount			25,065	163,019
Stock issued for services				120,000
Finance charges	137,397		137,397
Change in value of derivative	521,179	170,264	832,562	157,492
Changes in operating assets and liabilities:
Due to Cytocom Inc.			27,954
Accounts payable			120,889	386,972
Inventories				82,801
Accrued liabilities			357,576	638,681
Net cash from/ (used in) operating activities			(94,658)	15,538
CASH FLOW FROM INVESTING ACTIVITES
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from issuance of notes payable			135,000
Net cash provided by financing activities			135,000
Net increase in cash and cash equivalents			40,432	15,538
Cash and cash equivalents at beginning of period			4,925	5,859
Cash and cash equivalents at end of period	$ 45,267	$ 21,397	45,267	21,397
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest				16,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITES:
Debt discounts on notes payable and warrants			135,000	73,000
Conversion of debt and accrued interest to common stock				27,110
Reclassification from notes payable to accounts payable				254,749
Debt settled and reclassified to accrued expenses				$ 35,325

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). On November 10, 2004, Galliano International Ltd. merged with Resort Clubs; Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, it executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. In October 2014, the name was changed to Immune Therapeutics, Inc. The Company initially focused on acquiring patents that would protect and advance the development of new uses of opioid-related immune therapies such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”) to stimulate and/or regulate the immune system to treat a variety of diseases. The Company believed that the therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer, all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. In a series of licensing agreements between the Company and Cytocom entered into between 2014 and 2020, in return for an up-front payment, the transfer of certain Company notes payable and other liabilities to Cytocom, and the payment of royalties by Cytocom on future sales, the Company transferred rights to Cytocom to develop and sell LDN and MENK for treatment in humans in the United States and certain other developed economies. The Company retained the right to develop and sell the licensed products in Emerging Markets. Under a May 2018 amendment to the licensing agreements, the royalty due from Cytocom was set at 1% of sales and the Company no longer had any ongoing obligations to pay for costs in connection with the assets of Cytocom. As a consequence of this amendment, the Company no longer consolidated the financial statements of Cytocom with its own statements. Under a December 2018 amendment, Cytocom became obligated to maintain Immune’s ownership at not less than 15.5% of Cytocom. At June 30, 2020, the Company’s equity interest in Cytocom stood at 14.34% of Cytocom’s issued and outstanding common stock. On February 27, 2020, the Company entered into a license agreement (the “License Agreement”) with Forte Biotechnology International Corp. (“Forte”), which granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. Forte is managed by Noreen Griffin, a former Chief Executive Officer of the Company. At present, the Company is a late development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for humans in Africa, Central and South America, the Caribbean and China. The Company is not permitted to market its licensed products in the United States. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at June 30, 2020 was not sufficient to meet the cash requirements to fund planned operations through for the next 12 months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss attributable to common shareholders of $803,546 during the three months ended June 30, 2020, resulting in stockholders’ deficit of $15,285,041 at that date.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2019 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2019. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Shares Issued and Outstanding On October 25, 2019, the Company closed voting by written consent as detailed in its Proxy Statement on form 14A, filed September 5, 2019 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (“Proxy Statement”). The Proxy Statement disclosed actions for which the Company was soliciting written consent, including consent to effect a reverse stock split of the Company’s issued and outstanding, but not authorized, common stock (the “Reverse Split”) at a ratio of 1,000-to-1. The Company’s shareholders approved the Reverse Split. The implementation of the shareholder approval is subject to approval by the Financial Industry Regulatory Authority (“FINRA”). In connection with our application to FINRA, on February 6, 2020, we filed Articles of Amendment to our Articles of Incorporation to effect the reverse stock split of our issued and outstanding, but not authorized, common stock at a ratio of 1 to 1,000. On March 12, 2020 we corrected a typographical error to reflect the proper ratio of 1 to 1,000 by the filing of Articles of Amendment to our Articles of Incorporation. Although we filed the Articles of Amendment at FINRA’s instruction, on June 9, 2020, we were advised by FINRA that our 1 for 1,000 reverse stock split would not be processed. By not processing the reverse stock split, quotations for our common stock do not reflect the 1 for 1,000 reverse stock split, which occurred on February 6, 2020. The financial statements accompanying this Form 10-Q are presented on the basis of the implementation of the reverse stock split. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2020, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 820, Fair Value Measurements Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2020 and June 30, 2019 was $319 and $691, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2020 and 2019, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2020, and 2019, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: At June 30, 2020 2019 Common Stock Purchase Warrants 19,290,036 4,211,061 Convertible Debt 78,066 152,720 Recent Accounting Standards During the quarter ended June 30, 2020, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	3. Accrued Liabilities Accrued expenses and other liabilities consist of the following: June 30, 2020 December 31, 2019 Accrued payroll $ 3,685,046 $ 3,610,810 Accrued interest and penalties – notes payable 1,098,246 899,904 Estimated legal settlements 166,057 136,057 Other accrued liabilities 45,000 48,217 Total accrued expenses and other liabilities $ 4,994,349 $ 4,694,988

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	4. Notes payable Notes payable consist of the following: June 30, 2020 December 31, 2019 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at June 30, 2020, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $675,994 earn interest at rates between 2% and 10% per annum. One loan, in the amount of $100,000, interest was payable in a fixed amount not tied to a specific interest rate. However, this note was extinguished and reassigned to a related party in 2019. The Company was unable to repay the remaining notes at maturity and at June 30, 2020 these notes were in default. 625,994 625,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at June 30, 2020 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at June 30, 2020 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As June 30, 2020, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and September 30, 2018. At June 30, 2020, the notes were in default. 500,000 500,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At June 30, 2020, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At June 30, 2020, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, the defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at June 30, 2020 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $1,486,204 derivative liability for the remaining conversion right. 454,032 454,032 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At June 30, 2020, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At June 30, 2020, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000 and 20,000 shares with an exercise price of $0.5. At June 30, 2020 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000 and 5,000 shares with an exercise price of $5. At June 30, 2020 the notes were in default 65,000 65,000 Promissory notes aggregating $208,000 issued in the third quarter of 2018, of which $3,000 is to a related party. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600 and 5,000 shares with an exercise price of $5. At June 30, 2020, the notes were in default. 208,000 198,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018, of which $210,000 is to a related party. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200 and 39,500 shares with an exercise price of $5 to $40. At June 30, 2020, the note was in default. 533,855 533,855 Promissory note for $23,000 issued to a related party in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600 shares with an exercise price of $5. At June 30, 2020, the note was in default. 23,000 23,000 Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matured in February 2020. At June 30, 2020, the notes were in default. 231,478 231,478 Promissory notes aggregating $50,000 issued in the second quarter of 2019, of which $40,000 is to a related party. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000 shares with an exercise price of $5. At June 30, 2020, the notes were in default. 50,000 50,000 Promissory note in the amount of $150,000 issued on October 1, 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15% per annum, with $1,875 due in monthly interest payments, and matures on April 30, 2021. 150,000 150,000 Promissory notes in the amount of $144,000 issued in the second quarter of 2020. The notes accrue interest at 12% per annum, and mature between March 31, 2021 and June 15, 2021. The Company has accrued a $416,880 derivative liability for the conversion rights attached to the notes. 144,000 - Less: Original issue discount on notes payable and warrants issued with notes. (118,932 ) - Total $ 5,580,439 $ 5,545,371 As of June 30, 2020, the Company had accrued $1,098,246 in unpaid interest and default penalties. During the quarter ended June 30, 2020, no shares were issued by the Company in settlement of promissory notes. As of June 30, 2019, the Company had accrued $959,412 in unpaid interest and default penalties. During the quarter ended June 30, 2019, no shares were issued by the Company in settlement of promissory notes.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	5 Derivative Liabilities As of June 30, 2020, and December 31, 2019 the aggregate fair value of the outstanding derivative liabilities was $1,903,085 and $798,126, respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter ended June 30, 2020: Three months ended June 30, 2020 Volatility 162.79 % Risk-free interest rate 0.16 % Expected dividends - % Expected term 1 year The Company determines the fair values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of June 30, 2020: Fair Value Measurements as of June 30, 2020 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 1,903,085 Total liabilities $ - $ - $ 1,903,085 The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Conversion Beginning balance $ 798,126 Additions 272,397 Change in fair value 832,562 Ending balance $ 1,903,085

Capital Structure - Common Stoc

Capital Structure - Common Stock and Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Capital Structure - Common Stock and Common Stock Purchase Warrants	6 Capital Structure – Common Stock and Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. Stock Warrants In the three months ended June 30, 2020, no new warrants were issued by the Company. There were no modifications of the terms of any warrants issued by the Company in the quarters ended June 30, 2020 and 2019. Following is a summary of outstanding stock warrants at, and activity during the six months ended, June 30, 2020: Number Exercise Price Weighted Average Price Warrants as of December 31, 2019 19,291,336 $ 0.05-500 $ 4.21 Issued - $ - $ - Expired and forfeited (1,300 ) $ 100-500 $ 192.31 Exercised - $ - $ - Warrants as of June 30, 2020 19,290,036 $ 0.05-200 $ 4.20 Summary of outstanding warrants as of June 30, 2020: Expiration Date Number of Shares Exercise Price Remaining Life (years) Fourth Quarter 2020 1,000 $ 200 0.50 First Quarter 2021 12,600 $ 200 0.75 Second Quarter 2021 5,812 $ 14-200 1.00 Third Quarter 2021 5,167 $ 30-200 1.25 Fourth Quarter 2021 300 $ 100 1.50 First Quarter 2022 150 $ 200 1.75 Second Quarter 2022 1,750 $ 150 2.00 Third Quarter 2022 1,650 $ 50-100 2.25 Fourth Quarter 2022 9,811 $ 80-290 2.50 First Quarter 2023 1,204,000 $ 0.05-40 2.75 Second Quarter 2023 802,000 $ 0.05-200 3.00 Third Quarter 2023 7,521,500 $ 0.05-100 3.25 Fourth Quarter 2023 6,024,300 $ 0.05-0.20 3.50 First Quarter 2024 3,660,000 $ 0.05 3.75 Second Quarter 2024 8,000 $ 5 4.00 Third Quarter 2028 3,000 $ 70 8.25 Second Quarter 2032 28,995 $ 10-70 12.00 19,290,036 $ 0.05-200

Stock Compensation

Stock Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock Compensation	7 Stock Compensation Shares Issued for Services During the quarters ended June 30, 2020 and 2019, the Company issued 0 and 3,000,000 shares of common stock respectively for consulting fees. The Company valued these shares at $0 and $120,000 respectively, based upon the fair value of the common stock at the dates of the agreements.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	8. Income Taxes – Results of Operations There was no income tax expense reflected in the results of operations for the years ended June 30, 2020 and 2019 because the Company incurred a net loss in both years. For U.S. federal purposes the corporate statutory income tax rate was 21%, for 2019 and 2020 tax years. The Company has recognized no tax benefit for the losses generated for the periods through June 30, 2020. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2020 and 2019 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year.

Licenses and Supply Agreements

Licenses and Supply Agreements	6 Months Ended
	Jun. 30, 2020
Licenses And Supply Agreements
Licenses and Supply Agreements	9. Licenses and Supply Agreements Patent and Subsidiary Acquisition In December 2014, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. The royalty due to Cytocom was reduced from 5% to 1% of sales and the Company no longer had any ongoing obligations to pay for the cost in connection with the assets of Cytocom. On May 13, 2020, the Company and Cytocom entered into Amendment to The Second Amendment to The License Agreement (“Third Amendment”) to their Second Amendment to The License Agreement that is effective December 31, 2018. The Third Amendment made changes to the lists of liabilities that were assigned by the Company to Cytocom on the effective date. Simultaneously with the Third Amendment, the companies signed a PRC Amendment to The Second Amendment to The License Agreement, in which they confirmed that the term “the Republic of China” in the Second Amendment means the People’s Republic of China and not The Republic of China, also known as Taiwan. On February 27, 2020, the Company approved and entered into a license agreement (the “License Agreement”) with Forte Biotechnology International Corp. (“Forte”). Under the License Agreement, the Company granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. As consideration for the license, Forte agreed to make certain license, milestone and royalty payments to the Company. Forte is managed by Noreen Griffin, a former Chief Executive Officer of the Company.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Due to the fact that AHAR Pharma failed to meet its contractual purchase obligations, the Company formally issued notice of default under the agreement. On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. Discussions between the Company and Fidson in the first half of 2020 did not result in any orders or shipments under this agreement. Contract Manufacturing Agreements On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At June 30, 2020, the Company was a party to an agreement to lease office space in Winter Park, Florida. Rental expense for the three months ended June 30, 2020 and 2019 was $177 and $2,162 respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events On July 22, 2020, director Kevin J. Phelps, interim president and CEO of the Company entered into a three-year executive employment agreement with the Company to serve as president and CEO. This agreement was formally approved by the Company’s Board as of July 24, 2020 with Mr. Phelps abstaining. While fully effective, the parties may expand and restate the Agreement within thirty days.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2019 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2019. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Shares Issued and Outstanding	Shares Issued and Outstanding On October 25, 2019, the Company closed voting by written consent as detailed in its Proxy Statement on form 14A, filed September 5, 2019 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (“Proxy Statement”). The Proxy Statement disclosed actions for which the Company was soliciting written consent, including consent to effect a reverse stock split of the Company’s issued and outstanding, but not authorized, common stock (the “Reverse Split”) at a ratio of 1,000-to-1. The Company’s shareholders approved the Reverse Split. The implementation of the shareholder approval is subject to approval by the Financial Industry Regulatory Authority (“FINRA”). In connection with our application to FINRA, on February 6, 2020, we filed Articles of Amendment to our Articles of Incorporation to effect the reverse stock split of our issued and outstanding, but not authorized, common stock at a ratio of 1 to 1,000. On March 12, 2020 we corrected a typographical error to reflect the proper ratio of 1 to 1,000 by the filing of Articles of Amendment to our Articles of Incorporation. Although we filed the Articles of Amendment at FINRA’s instruction, on June 9, 2020, we were advised by FINRA that our 1 for 1,000 reverse stock split would not be processed. By not processing the reverse stock split, quotations for our common stock do not reflect the 1 for 1,000 reverse stock split, which occurred on February 6, 2020. The financial statements accompanying this Form 10-Q are presented on the basis of the implementation of the reverse stock split.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2020, the Company has no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 820, Fair Value Measurements
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2020 and June 30, 2019 was $319 and $691, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2020 and 2019, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2020, and 2019, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: At June 30, 2020 2019 Common Stock Purchase Warrants 19,290,036 4,211,061 Convertible Debt 78,066 152,720
Recent Accounting Standards	Recent Accounting Standards During the quarter ended June 30, 2020, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: At June 30, 2020 2019 Common Stock Purchase Warrants 19,290,036 4,211,061 Convertible Debt 78,066 152,720

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: June 30, 2020 December 31, 2019 Accrued payroll $ 3,685,046 $ 3,610,810 Accrued interest and penalties – notes payable 1,098,246 899,904 Estimated legal settlements 166,057 136,057 Other accrued liabilities 45,000 48,217 Total accrued expenses and other liabilities $ 4,994,349 $ 4,694,988

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following: June 30, 2020 December 31, 2019 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at June 30, 2020, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $675,994 earn interest at rates between 2% and 10% per annum. One loan, in the amount of $100,000, interest was payable in a fixed amount not tied to a specific interest rate. However, this note was extinguished and reassigned to a related party in 2019. The Company was unable to repay the remaining notes at maturity and at June 30, 2020 these notes were in default. 625,994 625,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at June 30, 2020 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at June 30, 2020 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As June 30, 2020, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and September 30, 2018. At June 30, 2020, the notes were in default. 500,000 500,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At June 30, 2020, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At June 30, 2020, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, the defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at June 30, 2020 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $1,486,204 derivative liability for the remaining conversion right. 454,032 454,032 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At June 30, 2020, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At June 30, 2020, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000 and 20,000 shares with an exercise price of $0.5. At June 30, 2020 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000 and 5,000 shares with an exercise price of $5. At June 30, 2020 the notes were in default 65,000 65,000 Promissory notes aggregating $208,000 issued in the third quarter of 2018, of which $3,000 is to a related party. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600 and 5,000 shares with an exercise price of $5. At June 30, 2020, the notes were in default. 208,000 198,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018, of which $210,000 is to a related party. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200 and 39,500 shares with an exercise price of $5 to $40. At June 30, 2020, the note was in default. 533,855 533,855 Promissory note for $23,000 issued to a related party in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600 shares with an exercise price of $5. At June 30, 2020, the note was in default. 23,000 23,000 Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matured in February 2020. At June 30, 2020, the notes were in default. 231,478 231,478 Promissory notes aggregating $50,000 issued in the second quarter of 2019, of which $40,000 is to a related party. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000 shares with an exercise price of $5. At June 30, 2020, the notes were in default. 50,000 50,000 Promissory note in the amount of $150,000 issued on October 1, 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15% per annum, with $1,875 due in monthly interest payments, and matures on April 30, 2021. 150,000 150,000 Promissory notes in the amount of $144,000 issued in the second quarter of 2020. The notes accrue interest at 12% per annum, and mature between March 31, 2021 and June 15, 2021. The Company has accrued a $416,880 derivative liability for the conversion rights attached to the notes. 144,000 - Less: Original issue discount on notes payable and warrants issued with notes. (118,932 ) - Total $ 5,580,439 $ 5,545,371

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended
	Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions	The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter ended June 30, 2020: Three months ended June 30, 2020 Volatility 162.79 % Risk-free interest rate 0.16 % Expected dividends - % Expected term 1 year
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of June 30, 2020: Fair Value Measurements as of June 30, 2020 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 1,903,085 Total liabilities $ - $ - $ 1,903,085
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Conversion Beginning balance $ 798,126 Additions 272,397 Change in fair value 832,562 Ending balance $ 1,903,085

Capital Structure - Common St_2

Capital Structure - Common Stock and Stock Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at, and activity during the six months ended, June 30, 2020: Number Exercise Price Weighted Average Price Warrants as of December 31, 2019 19,291,336 $ 0.05-500 $ 4.21 Issued - $ - $ - Expired and forfeited (1,300 ) $ 100-500 $ 192.31 Exercised - $ - $ - Warrants as of June 30, 2020 19,290,036 $ 0.05-200 $ 4.20
Summary of Outstanding Warrants	Summary of outstanding warrants as of June 30, 2020: Expiration Date Number of Shares Exercise Price Remaining Life (years) Fourth Quarter 2020 1,000 $ 200 0.50 First Quarter 2021 12,600 $ 200 0.75 Second Quarter 2021 5,812 $ 14-200 1.00 Third Quarter 2021 5,167 $ 30-200 1.25 Fourth Quarter 2021 300 $ 100 1.50 First Quarter 2022 150 $ 200 1.75 Second Quarter 2022 1,750 $ 150 2.00 Third Quarter 2022 1,650 $ 50-100 2.25 Fourth Quarter 2022 9,811 $ 80-290 2.50 First Quarter 2023 1,204,000 $ 0.05-40 2.75 Second Quarter 2023 802,000 $ 0.05-200 3.00 Third Quarter 2023 7,521,500 $ 0.05-100 3.25 Fourth Quarter 2023 6,024,300 $ 0.05-0.20 3.50 First Quarter 2024 3,660,000 $ 0.05 3.75 Second Quarter 2024 8,000 $ 5 4.00 Third Quarter 2028 3,000 $ 70 8.25 Second Quarter 2032 28,995 $ 10-70 12.00 19,290,036 $ 0.05-200

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	May 01, 2018	Dec. 31, 2014	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Net loss attributable to common shareholders			$ (803,546)	$ (824,709)	$ (1,596,420)	$ (1,534,118)
Stockholder's deficit			$ (15,285,041)	$ (12,529,322)	$ (15,285,041)	$ (12,529,322)	$ (13,688,621)	$ (11,250,638)
Cytocom Inc., [Member]
Ownership percentage			14.34%		14.34%
Licensing Agreement [Member]
Ownership percentage								15.50%
Cytocom Inc., [Member]
Royalty percentage		5.00%
Cytocom Inc., [Member] | Licensing Agreement [Member]
Royalty percentage	1.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Maximum of annual gross revenue					$ 1,000,000,000
Reverse split			Common stock (the "Reverse Split") at a ratio of 1,000-to-1.
Federal deposit insurance corporation value	$ 250,000		$ 250,000
Depreciation expense	319	$ 691	319	$ 691
Accrued interest or penalties related to uncertain tax positions
FINRA [Member]
Reverse split			In connection with our application to FINRA, on February 6, 2020, we filed Articles of Amendment to our Articles of Incorporation to effect the reverse stock split of our issued and outstanding, but not authorized, common stock at a ratio of 1 to 1,000. On March 12, 2020 we corrected a typographical error to reflect the proper ratio of 1 to 1,000 by the filing of Articles of Amendment to our Articles of Incorporation. Although we filed the Articles of Amendment at FINRA's instruction, on June 9, 2020, we were advised by FINRA that our 1 for 1,000 reverse stock split would not be processed. By not processing the reverse stock split, quotations for our common stock do not reflect the 1 for 1,000 reverse stock split, which occurred on February 6, 2020.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Common Stock Purchase Warrants [Member]
Potentially dilutive securities	19,290,036	4,211,061
Convertible Debt [Member]
Potentially dilutive securities	78,066	152,720

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued payroll	$ 3,685,046	$ 3,610,810
Accrued interest and penalties - notes payable	1,098,246	899,904
Estimated legal settlements	166,057	136,057
Other accrued liabilities	45,000	48,217
Total accrued expenses and other liabilities	$ 4,994,349	$ 4,694,988

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accrued unpaid interest and default penalties	$ 1,098,246	$ 959,412
Settlement of Promissory Notes [Member]
Issuance of common stock for conversion of debt, shares

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Total	$ 5,580,439	$ 5,545,371
Less: Original issue discount on notes payable and warrants issued with notes.	(118,932)
Notes Payable One [Member]
Total	286,000	286,000
Notes Payable Two [Member]
Total	625,994	625,994
Notes Payable Three [Member]
Total	97,737	97,737
Notes Payable Four [Member]
Total	206,000	206,000
Notes Payable Five [Member]
Total	1,354,000	1,354,000
Notes Payable Six [Member]
Total	500,000	500,000
Notes Payable Seven [Member]
Total	300,000	300,000
Notes Payable Eight [Member]
Total	191,800	191,800
Notes Payable Nine [Member]
Total	454,032	454,032
Notes Payable Ten [Member]
Total	105,500	105,500
Notes Payable Eleven [Member]
Total	47,975	47,975
Notes Payable Twelve [Member]
Total	125,000	125,000
Notes Payable Thirteen [Member]
Total	65,000	65,000
Notes Payable Fourteen [Member]
Total	208,000	198,000
Notes Payable Fifteen [Member]
Total	533,855	533,855
Notes Payable Sixteen [Member]
Total	23,000	23,000
Notes Payable Seventeen [Member]
Total	231,478	231,478
Notes Payable Eighteen [Member]
Total	50,000	50,000
Notes Payable Nineteen [Member]
Total	150,000	150,000
Notes Payable Twenty [Member]
Total	$ 144,000

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)

Oct. 02, 2019USD ($)

Nov. 03, 2015

Jun. 30, 2020USD ($)

Jun. 30, 2019USD ($)$ / sharesshares

Mar. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2018USD ($)$ / sharesshares

Mar. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Jun. 30, 2018USD ($)$ / sharesshares

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)Installments

Dec. 31, 2016USD ($)

Dec. 31, 2017USD ($)

Oct. 31, 2017USD ($)

Notes Payable One [Member]

Percentage of interest rate per annum

10.00%

Number of installments, months | Installments

36

Notes Payable One [Member] | Maximum [Member]

Maximum amount raise in debt

$ 2,000,000

Notes Payable Two [Member] | Lenders [Member]

Debt instrument maturity date description

June 14, 2015 and December 1, 2017

Aggregating loan

$ 675,994

$ 675,994

$ 675,994

Accrued interest

$ 100,000

$ 100,000

$ 100,000

Notes Payable Two [Member] | Maximum [Member] | Lenders [Member]

Percentage of interest rate per annum

10.00%

10.00%

10.00%

Notes Payable Two [Member] | Minimum [Member] | Lenders [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Notes Payable Three [Member]

Percentage of interest rate per annum

10.00%

Note matures date

Nov. 3, 2016

Notes Payable Four [Member] | Lenders [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Note matures date

Dec. 31, 2017

Notes Payable Five [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Debt instrument maturity date description

November 1, 2017 and December 31, 2017

Notes aggregating default amount

$ 1,350,000

$ 1,350,000

$ 1,350,000

Notes Payable Six [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 12, 2018 and September 30, 2018

Notes aggregating default amount

$ 500,000

Notes Payable Seven [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

April 3, 2018 and May 31, 2018

Notes aggregating default amount

$ 300,000

Notes Payable Eight [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

June 16, 2018 and December 31, 2018

Notes aggregating default amount

$ 191,800

Notes Payable Nine [Member]

Maximum amount raise in debt

$ 454,032

Accrued interest

49,943

Notes aggregating default amount

$ 425,000

Original issuance discount

$ 70,000

Derivative liability

$ 1,486,204

Notes Payable Ten [Member]

Percentage of interest rate per annum

2.00%

Notes aggregating default amount

$ 105,500

Notes Payable Eleven [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018 and January 2019

Notes aggregating default amount

$ 47,975

Notes Payable Twelve [Member]

Debt instrument maturity date description

April 2018 and June 2018

Notes aggregating default amount

$ 125,000

Warrant exercise price per share | $ / shares

$ 0.5

Notes Payable Twelve [Member] | Maximum [Member]

Percentage of interest rate per annum

12.00%

Number of warrants | shares

20,000

Notes Payable Twelve [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

5,000

Notes Payable Thirteen [Member]

Percentage of interest rate per annum

2.00%

2.00%

Debt instrument maturity date description

July 2018 and October 2018

Notes aggregating default amount

$ 65,000

$ 65,000

Warrant exercise price per share | $ / shares

$ 5

$ 5

Notes Payable Thirteen [Member] | Maximum [Member]

Number of warrants | shares

5,000

5,000

Notes Payable Thirteen [Member] | Minimum [Member]

Number of warrants | shares

1,000

1,000

Notes Payable Fourteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

November 2018 and January 2019

Notes aggregating default amount

$ 208,000

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Fourteen [Member] | Related Party [Member]

Notes aggregating default amount

$ 3,000

Notes Payable Fourteen [Member] | Maximum [Member]

Number of warrants | shares

5,000

Notes Payable Fourteen [Member] | Minimum [Member]

Number of warrants | shares

600

Notes Payable Fifteen [Member]

Debt instrument maturity date description

February 2019 and December 2019

Notes aggregating default amount

$ 533,855

Notes Payable Fifteen [Member] | Related Party [Member]

Notes aggregating default amount

$ 210,000

Notes Payable Fifteen [Member] | Maximum [Member]

Percentage of interest rate per annum

3.50%

Number of warrants | shares

39,500

Warrant exercise price per share | $ / shares

$ 40

Notes Payable Fifteen [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

200

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Sixteen [Member]

Percentage of interest rate per annum

2.00%

Note matures date

Jul. 31, 2019

Notes aggregating default amount

$ 23,000

Number of warrants | shares

4,600

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Seventeen [Member]

Percentage of interest rate per annum

6.00%

Note matures date

Feb. 29, 2020

Notes aggregating default amount

$ 231,478

Notes Payable Eighteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July and September 2019

Notes aggregating default amount

$ 50,000

Number of warrants | shares

10,000

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Eighteen [Member] | Related Party [Member]

Notes aggregating default amount

$ 40,000

Notes Payable Nineteen [Member]

Percentage of interest rate per annum

15.00%

Note matures date

Apr. 30, 2021

Notes aggregating default amount

$ 150,000

Debt instrument, periodic payment, principal

$ 1,875

Notes Payable Twenty [Member]

Percentage of interest rate per annum

12.00%

Debt instrument maturity date description

March 31, 2021 and June 15, 2021

Notes aggregating default amount

$ 144,000

Derivative liability

$ 416,880

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities	$ 1,903,085	$ 798,126

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions (Details) - Black-Scholes Option Pricing Model [Member]	3 Months Ended
	Jun. 30, 2020
Volatility [Member]
Fair value assumptions, measurement input, percentages	162.79
Risk-Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	0.16
Expected Dividends [Member]
Fair value assumptions, measurement input, percentages	0
Expected Term [Member]
Fair value assumptions, measurement input, term	1 year

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Valuation of Financial Instruments (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Total liabilities	$ 15,330,881	$ 13,694,437
Level 1 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 2 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 3 [Member]
Total assets
Conversion option derivative liability	1,903,085
Total liabilities	$ 1,903,085

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details) - Level 3 [Member]	6 Months Ended
	Jun. 30, 2020USD ($)
Derivative liabilities beginning balance	$ 798,126
Additions	272,397
Change in fair value	832,562
Derivative liabilities ending balance	$ 1,903,085

Capital Structure - Common St_3

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - Warrant [Member] - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Number of warrants issued during period
Modification of warrant issued

Capital Structure - Common St_4

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Shares Warrants, Beginning balance | shares	19,291,336
Number of Shares Warrants, Issued | shares
Number of Shares Warrants, Expired and forfeited | shares	(1,300)
Number of Shares Warrants, Exercised | shares
Number of Shares Warrants, Ending balance | shares	19,290,036
Exercise Price, Issued
Exercise Price, Exercised
Weighted Average Price, Beginning balance	4.21
Weighted Average Price, Issued
Weighted Average Price, Expired and forfeited	192.31
Weighted Average Price, Exercised
Weighted Average Price, Ending balance	4.20
Maximum [Member]
Exercise Price, Beginning balance	0.05
Exercise Price, Expired and forfeited	100
Exercise Price, Ending balance	0.05
Minimum [Member]
Exercise Price, Beginning balance	500
Exercise Price, Expired and forfeited	500
Exercise Price, Ending balance	$ 200

Capital Structure - Common St_5

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Shares | shares	19,290,036
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 200
Fourth Quarter 2020 [Member]
Number of Shares | shares	1,000
Exercise Price Upper Limit	$ 200
Remaining Life (years)	6 months
First Quarter 2021 [Member]
Number of Shares | shares	12,600
Exercise Price Upper Limit	$ 200
Remaining Life (years)	9 months
Second Quarter 2021 [Member]
Number of Shares | shares	5,812
Exercise Price Lower Limit	$ 14
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year
Third Quarter 2021 [Member]
Number of Shares | shares	5,167
Exercise Price Lower Limit	$ 30
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year 2 months 30 days
Fourth Quarter 2021 [Member]
Number of Shares | shares	300
Exercise Price Upper Limit	$ 100
Remaining Life (years)	1 year 6 months
First Quarter 2022 [Member]
Number of Shares | shares	150
Exercise Price Upper Limit	$ 200
Remaining Life (years)	1 year 9 months
Second Quarter 2022 [Member]
Number of Shares | shares	1,750
Exercise Price Upper Limit	$ 150
Remaining Life (years)	2 years
Third Quarter 2022 [Member]
Number of Shares | shares	1,650
Exercise Price Lower Limit	$ 50
Exercise Price Upper Limit	$ 100
Remaining Life (years)	2 years 2 months 30 days
Fourth Quarter 2022 [Member]
Number of Shares | shares	9,811
Exercise Price Lower Limit	$ 80
Exercise Price Upper Limit	$ 290
Remaining Life (years)	2 years 6 months
First Quarter 2023 [Member]
Number of Shares | shares	1,204,000
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 40
Remaining Life (years)	2 years 9 months
Second Quarter 2023 [Member]
Number of Shares | shares	802,000
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 200
Remaining Life (years)	3 years
Third Quarter 2023 [Member]
Number of Shares | shares	7,521,500
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 100
Remaining Life (years)	3 years 2 months 30 days
Fourth Quarter 2023 [Member]
Number of Shares | shares	6,024,300
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years 6 months
First Quarter 2024 [Member]
Number of Shares | shares	3,660,000
Exercise Price Upper Limit	$ 0.05
Remaining Life (years)	3 years 9 months
Second Quarter 2024 [Member]
Number of Shares | shares	8,000
Exercise Price Upper Limit	$ 5
Remaining Life (years)	4 years
Third Quarter 2028 [Member]
Number of Shares | shares	3,000
Exercise Price Upper Limit	$ 70
Remaining Life (years)	8 years 2 months 30 days
Second Quarter 2032 [Member]
Number of Shares | shares	28,995
Exercise Price Lower Limit	$ 10
Exercise Price Upper Limit	$ 70
Remaining Life (years)	12 years

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2019
Number of common stock issued for services, values			$ 120,000
Consulting Fees [Member]
Number of common stock issued for services	0	3,000,000
Number of common stock issued for services, values	$ 0	$ 120,000

Income Taxes - Results of Ope_2

Income Taxes - Results of Operations (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax expense
Percentage of statutory income tax rate	21.00%	21.00%
Effective tax rate	0.00%	0.00%

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - Cytocom Inc., [Member]	May 01, 2018	Dec. 31, 2014
Royalty percentage		5.00%
Licensing Agreement [Member]
Royalty percentage	1.00%
Maximum [Member] | Restated Agreement [Member]
Royalty percentage	5.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Rental expense	$ 177	$ 2,162

Subsequent Events (Detail Narra

Subsequent Events (Detail Narrative)	Jul. 22, 2020
Subsequent Event [Member] | Kevin J. Phelps [Member] | Employment Agreement [Member]
Agreement description	On July 22, 2020, director Kevin J. Phelps, interim president and CEO of the Company entered into a three-year executive employment agreement with the Company to serve as president and CEO. This agreement was formally approved by the Company's Board as of July 24, 2020 with Mr. Phelps abstaining. While fully effective, the parties may expand and restate the Agreement within thirty days.